Literature DB >> 22300025

Development of radioligands for the imaging of α7 nicotinic acetylcholine receptors with positron emission tomography.

Peter Brust1, Dan Peters, Winnie Deuther-Conrad.   

Abstract

Molecular imaging of brain structures by highly sensitive non-invasive techniques offers unique possibilities in the understanding of physiological and pathological processes in the central nervous system. In particular, the quantitative analysis by positron emission tomography (PET) of α7 nicotinic acetylcholine receptors (α7 nAChR), which are involved in different signalling pathways in the brain, is assumed to provide important information on the relation between receptor dysfunction and the pathogeneses of neuropsychiatric brain diseases, but the applicability of this imaging approach is still hampered due to insufficient imaging agents. This paper presents the recent efforts made to develop PET radiotracers targeting α7 nAChR as well as the current state of the evaluation of the most promising radiolabelled compounds in animal models and humans.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22300025     DOI: 10.2174/138945012800398955

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  8 in total

Review 1.  Development of (18)F-labeled radiotracers for neuroreceptor imaging with positron emission tomography.

Authors:  Peter Brust; Jörg van den Hoff; Jörg Steinbach
Journal:  Neurosci Bull       Date:  2014-08-29       Impact factor: 5.203

2.  Human brain imaging of α7 nAChR with [(18)F]ASEM: a new PET radiotracer for neuropsychiatry and determination of drug occupancy.

Authors:  Dean F Wong; Hiroto Kuwabara; Martin Pomper; Daniel P Holt; James R Brasic; Noble George; Boris Frolov; William Willis; Yongjun Gao; Heather Valentine; Ayon Nandi; Lorena Gapasin; Robert F Dannals; Andrew G Horti
Journal:  Mol Imaging Biol       Date:  2014-10       Impact factor: 3.488

3.  Derivatives of dibenzothiophene for positron emission tomography imaging of α7-nicotinic acetylcholine receptors.

Authors:  Yongjun Gao; Kenneth J Kellar; Robert P Yasuda; Thao Tran; Yingxian Xiao; Robert F Dannals; Andrew G Horti
Journal:  J Med Chem       Date:  2013-09-19       Impact factor: 7.446

4.  Longitudinal PET Imaging of α7 Nicotinic Acetylcholine Receptors with [18F]ASEM in a Rat Model of Parkinson's Disease.

Authors:  Steven Vetel; Johnny Vercouillie; Frédéric Buron; Jackie Vergote; Clovis Tauber; Julie Busson; Gabrielle Chicheri; Sylvain Routier; Sophie Sérrière; Sylvie Chalon
Journal:  Mol Imaging Biol       Date:  2020-04       Impact factor: 3.488

5.  PET imaging of α7 nicotinic acetylcholine receptors: a comparative study of [18F]ASEM and [18F]DBT-10 in nonhuman primates, and further evaluation of [18F]ASEM in humans.

Authors:  Ansel T Hillmer; Songye Li; Ming-Qiang Zheng; Matthias Scheunemann; Shu-Fei Lin; Nabeel Nabulsi; Daniel Holden; Richard Pracitto; David Labaree; Jim Ropchan; Rodrigo Teodoro; Winnie Deuther-Conrad; Irina Esterlis; Kelly P Cosgrove; Peter Brust; Richard E Carson; Yiyun Huang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-01-24       Impact factor: 9.236

6.  PET imaging evaluation of [(18)F]DBT-10, a novel radioligand specific to α7 nicotinic acetylcholine receptors, in nonhuman primates.

Authors:  Ansel T Hillmer; Ming-Qiang Zheng; Songye Li; Matthias Scheunemann; Shu-fei Lin; Daniel Holden; David Labaree; Jim Ropchan; Rodrigo Teodoro; Winnie Deuther-Conrad; Richard E Carson; Peter Brust; Yiyun Huang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-10-12       Impact factor: 9.236

Review 7.  PET Imaging of the Human Nicotinic Cholinergic Pathway in Atherosclerosis.

Authors:  Matthias Bauwens; Felix M Mottaghy; Jan Bucerius
Journal:  Curr Cardiol Rep       Date:  2015-08       Impact factor: 2.931

Review 8.  Translational utility of rodent hippocampal auditory gating in schizophrenia research: a review and evaluation.

Authors:  J Smucny; K E Stevens; A Olincy; J R Tregellas
Journal:  Transl Psychiatry       Date:  2015-06-23       Impact factor: 6.222

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.